Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 2022 | 55 pages | ID: B6519D61EDAFEN
Global Markets Direct

Abstracts

Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 5 and 4 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Becker Muscular Dystrophy - Overview
Becker Muscular Dystrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Becker Muscular Dystrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
ARMGO Pharma Inc
Edgewise Therapeutics Inc
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PhaseBio Pharmaceuticals Inc
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Scholar Rock Inc
Stealth BioTherapeutics Corp
Tivorsan Pharmaceuticals Inc
Becker Muscular Dystrophy - Drug Profiles
apitegromab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dextro epicatechin - Drug Profile
Product Description
Mechanism Of Action
History of Events
EDG-5506 - Drug Profile
Product Description
Mechanism Of Action
History of Events
elamipretide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
epicatechin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile
Product Description
Mechanism Of Action
History of Events
givinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
nandrolone decanoate - Drug Profile
Product Description
Mechanism Of Action
PB-1023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TVN-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vamorolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
Becker Muscular Dystrophy - Dormant Projects
Becker Muscular Dystrophy - Discontinued Products
Becker Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Apr 14, 2022: Edgewise-Funded natural history trial of Becker Muscular Dystrophy (BMD) now enrolling
Mar 08, 2022: Edgewise Therapeutics to present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference
Jan 05, 2022: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1b clinical trial in adults with Becker Muscular Dystrophy (BMD)
Dec 15, 2021: Edgewise Therapeutics to report phase 1b topline results of EDG-5506 in individuals with Becker muscular dystrophy (BMD) on January 5, 2022, and initiates ARCH follow-on open label BMD study
Oct 28, 2021: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1 multiple ascending dose (MAD) study in healthy volunteers (HVs) and doses first Becker Muscular Dystrophy (BMD) patients
Sep 27, 2021: ReveraGen and Santhera announce FDA orphan grant funding for clinical trial with vamorolone in Becker muscular dystrophy
Aug 16, 2021: Edgewise receives U.S. FDA Fast Track Designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy (BMD)
Jun 26, 2021: Italfarmaco announces topline data from phase 2 trial with Givinostat in patients with Becker Muscular Dystrophy
May 04, 2021: Edgewise Therapeutics announces publication of data demonstrating the elevation of fast but not slow skeletal muscle fiber injury biomarkers in the circulation of patients with Becker and Duchenne Muscular Dystrophy
Feb 22, 2021: Italfarmaco provides update on ongoing clinical programs with givinostat in oral presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy
Nov 11, 2020: Edgewise Therapeutics initiates phase 1 clinical trial of EDG-5506 in Becker muscular dystrophy
Oct 29, 2020: Edgewise Therapeutics appoints John Moore as general counsel
Aug 12, 2020: Epirium Bio announces commencement of phase 1 clinical trial of EPM-01 in Becker muscular dystrophy
Apr 14, 2020: Epirium Bio receives FDA orphan-drug designation for EB 002 ((+)-Epicatechin) for the treatment of duchenne and becker muscular dystrophy
Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Becker Muscular Dystrophy, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Becker Muscular Dystrophy - Pipeline by ARMGO Pharma Inc, 2022
Becker Muscular Dystrophy - Pipeline by Edgewise Therapeutics Inc, 2022
Becker Muscular Dystrophy - Pipeline by Epirium Bio Inc, 2022
Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, 2022
Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, 2022
Becker Muscular Dystrophy - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Becker Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, 2022
Becker Muscular Dystrophy - Pipeline by Sarcomed AB, 2022
Becker Muscular Dystrophy - Pipeline by Scholar Rock Inc, 2022
Becker Muscular Dystrophy - Pipeline by Stealth BioTherapeutics Corp, 2022
Becker Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, 2022
Becker Muscular Dystrophy - Dormant Projects, 2022
Becker Muscular Dystrophy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Becker Muscular Dystrophy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022